Assessing Synopsys (SNPS) Valuation After Elliott Investment And Expanded Arm AGI CPU Collaboration

Synopsys (SNPS) has drawn fresh attention after announcing a private placement of several billion dollars in common shares that brought in Elliott Investment Management as a new investor, together with its expanded Arm AGI CPU collaboration.

See our latest analysis for Synopsys.

The share price has been under pressure in recent months, with a 30 day share price return of 10.48% and a 90 day share price return of 17.58%. At the same time, the 1 year total shareholder return sits at 2.01% and the 5 year total shareholder return at 51.21%. This suggests long term holders have still seen gains while recent news around the Elliott investment and the expanded Arm AGI CPU collaboration has coincided with fading momentum.

If you are looking beyond Synopsys for other AI related ideas, this could be a good moment to scan the market using our list of 66 profitable AI stocks that aren't just burning cash

With Synopsys trading at US$395.95 and only a small intrinsic discount indicated, yet sitting well below some published analyst targets, the key question is simple: is this a genuine entry point or is future growth already fully priced in?

Most Popular Narrative: 26.4% Undervalued

Against the last close of $395.95, the most followed narrative still anchors on a fair value of $537.75, built on detailed growth and margin assumptions.

The acquisition and integration of Ansys positions Synopsys as the global leader in engineering solutions from silicon to systems, dramatically expanding its addressable market into sectors like automotive, industrial, and aerospace. This should drive long-term top-line growth as more sophisticated and complex products (especially AI-powered and smart devices) require robust simulation, analysis, and EDA tools.

Read the complete narrative.

Curious what kind of revenue path, margin profile, and future earnings multiple are baked into that valuation gap? The full narrative spells out a very specific growth runway.

Result: Fair Value of $537.75 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on export risks tied to China and the Ansys integration, where higher costs, execution issues, or slower IP monetisation could quickly challenge that upside.

Find out about the key risks to this Synopsys narrative.

Another Way To Look At Valuation

Analyst models point to a fair value of $537.75, but the current P/E of 68.6x tells a different story. That is well above the US Software average of 30x, the peer average of 38.7x, and a fair ratio of 43.7x that the market could eventually lean toward. For you, that gap means paying a premium today and accepting the risk that sentiment, growth, or both would need to justify it over time. So is this a small mispricing or a sign expectations are already stretched?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Seeing both optimism and concern in these numbers and narratives, it makes sense to act while the details are fresh and test the assumptions yourself. A good starting point is to weigh the 3 key rewards and 3 important warning signs.

Ready To Find Your Next Idea?

Do not stop your research with one stock. Broaden your watchlist now so you are not looking back later wishing you had moved sooner.

• Spot potential value opportunities early by scanning 59 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them yet.
• Strengthen your downside protection by reviewing 68 resilient stocks with low risk scores built around companies with more resilient risk profiles.
• Get ahead of the crowd by checking the screener containing 25 high quality undiscovered gems that focus on quality businesses still flying under most investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com